Peptide Neuromodulation in Autism Spectrum Disorder: Targeting Neuroinflammation, Mitochondrial Dysfunction, and Synaptic Plasticity

💡 About the Article:
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition with no FDA-approved treatments targeting its core biological mechanisms. This review explores the promising role of therapeutic peptides in modulating the underlying neurobiology of ASD.

📌 Key Highlights:

✔️ Peptides can cross the blood-brain barrier and target neuroinflammation, synaptic plasticity, and mitochondrial dysfunction
✔️ Mitochondria-derived peptides (MDPs) like Humanin, MOTS-c, and SHLP2 enhance neuronal survival, reduce oxidative stress, and modulate immune responses
✔️ Nano Organo Peptides (NOPs) and Mitochondrial Organelle (MO) Peptides represent next-gen therapies for metabolic restoration, neuroimmune modulation, and synaptic repair
✔️ Clinical studies on peptides like Oxytocin, VIP, Melatonin show early promise in improving social behaviors, sleep, and reducing neuroinflammation in ASD
✔️ Peptide therapies may bridge neurobiology with precision therapeutics, offering a path toward true disease-modifying interventions for ASD

MORE PUBLICATIONS:
https://european-wellness.eu/publications/